Research Article| Volume 182, P136-139, November 2014

Lactobacillus plantarum P17630 for preventing Candida vaginitis recurrence: a retrospective comparative study

Published:September 17, 2014DOI:



      Recurrence is a frequent complaint of patients with vulvovaginal candidiasis (VVC). Although the pathogenesis of VVC remains a controversial issue, disruption of the balance between the vaginal microbiota may facilitate overgrowth by Candida. Some probiotic bacterial strains can suppress Candida albicans; Lactobacillus plantarum P17630 is able to attach to vaginal epithelial cells and significantly reduce the adhesion of C. albicans.


      To evaluate the effect of the application of Lactobacillus plantarum P17630 in restoring the vaginal microbiota and prevention of relapses among women with acute VVC undergoing conventional (azole) local and main therapy.


      Retrospective comparative study. We recruited 89 women with a diagnosis of VVC, who were placed into two groups on the basis of reported treatment. The control group was treated with a daily dose of 2% clotrimazole vaginal cream at bedtime for 3 days, followed by vaginal application of a capsule containing lubricant once a day for 6 days and then once a week for another 4 weeks. The probiotic group was treated with the same azole-based protocol but followed by vaginal application of a capsule containing Lactobacillus plantarum P17630 (>108 CFU) once a day for 6 days and then once a week for another 4 weeks beginning the day following clotrimazole discontinuation. Clinical and diagnostic patterns were monitored for three months of follow-up.


      At the end of study the probiotic-treated women showed a statistically significant increase in Lactobacillus values “+++” (80% versus 40%, p < 0.001) and a better subjective resolution of symptoms such as vaginal discomfort described as burning or itching (90% versus 67.5%, p < 0.03). Among controls there was a non-significant increase at 3 months of recurrence of infection, but a significant increase of women with value of pH = 5 or >5.


      Although the results of different studies are controversial, most have suggested use of probiotics in the prevention or treatment of VVC, and no adverse effects have been reported. Our data with L. plantarum P17630 (Gyno-Canesflor - Bayer) confirm the role of this specific strain as a potential empirical preventive agent for reducing vaginal discomfort after conventional treatment of acute VVC and shifting the vaginal milieu toward a predominance of lactobacilli with an improvement of the vaginal pH value.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


        • Quan M.
        Vaginitis: diagnosis and management.
        Postgrad Med. 2010; 122: 117-127
        • Bohbot J.M.
        • Sednaoui P.
        • Verriere F.
        • et al.
        The etiologic diversity of vaginitis.
        Gynecol Obstet Fertil. 2012; 40: 578-581
        • Mashburn J.
        Vaginal infections update.
        J Midwifery Womens Health. 2012; 57: 629-634
        • Silva S.
        • Negri M.
        • Henriques M.
        • et al.
        Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance.
        FEMS Microbiol Rev. 2012; 36: 288-305
        • Smeekens S.P.
        • Van de Veerdonk F.L.
        • Kullberg B.J.
        • et al.
        Genetic susceptibility to Candida infections.
        EMBO Mol Med. 2013; 5: 805-813
        • Workowski K.A.
        • Berman S.
        Centers for disease control and prevention (CDC) Atlanta, C., sexually transmitted diseases treatment guidelines.
        Morb Mortal Wkly Rep. 2010; 59: 1-110
        • Sobel J.D.
        Factors involved in patient choice of oral or vaginal treatment for vulvovaginal candidiasis.
        Patient Prefer Adherence. 2013; 16: 31-34
        • Osset J.
        • García E.
        • Bartolomé R.M.
        • et al.
        Role of Lactobacillus as protector against vaginal candidiasis.
        Med Clin (Barc). 2001; 117: 285-288
        • Barbés C.
        • Boris S.
        Potential role of lactobacilli as prophylactic agents against genital pathogens.
        AIDS Patient Care STDS. 1999; 13: 747-751
        • Velraeds M.M.
        • Van der Mei H.C.
        • Reid G.
        • et al.
        Inhibition of initial adhesion of uropathogenic Enterococcus faecalis by biosurfactants from Lactobacillus isolates.
        Appl Environ Microbiol. 1996; 62: 1958-1963
        • Spurbeck R.R.
        • Arvidson C.G.
        Lactobacilli at the front line of defense against vaginally acquired infections.
        Future Microbiol. 2011; 6: 567-582
        • MacPhee R.A.
        • Hummelen R.
        • Bisanz J.E.
        • et al.
        Probiotic strategies for the treatment and prevention of bacterial vaginosis.
        Expert Opin Pharmacother. 2010; 11: 2985-2995
        • Martinez R.C.
        • Seney S.L.
        • Summers K.L.
        • et al.
        Effect of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 on the ability of Candida albicans to infect cells and induce inflammation.
        Microbiol Immunol. 2009; 53: 487-495
        • Bolton M.
        • van der Straten A.
        • Cohen C.R.
        Probiotics: potential to prevent HIV and sexually transmitted infections in women.
        Sex Transm Dis. 2008; 35: 214-225
        • Wylie J.G.
        • Henderson A.
        Identity and glycogen-fermenting ability of lactobacilli isolated from the vagina of pregnant women.
        J Med Microbiol. 1969; 3: 363-366
        • Giorgi A.
        • Torriani S.
        • Dellaglio F.
        • et al.
        Identification of vaginal lactobacilli from asymptomatic women.
        Microbiologica. 1987; 10: 377-384
        • Reid G.
        Probiotics: how microorganisms compete.
        JAMA. 1996; 276: 29-30
        • Culici M.
        • Dal Sasso M.
        • Braga P.C.
        L’Adesione del Lactobacillus plantarum P17630 alle cellule vaginali inibisce l’adesività della Candida albicans.
        Med Odontoiatrica Clin. 2004; 8: 34-41
        • Carriero C.
        • Lezzi V.
        • Mancini T.
        • et al.
        Vaginal capsules of Lactobacillus plantarum P17630 for prevention of relapse of candida vulvovaginitis: an Italian multicentre observational study.
        Int J Probiotics Prebiotics. 2007; 2: 155-162
        • Sobel J.D.
        • Chaim W.
        Vaginal microbiology of women with acute recurrent vulvovaginal candidiasis.
        J Clin Microbiol. 1996; 34: 2497-2499
        • Han T.L.
        • Cannon R.D.
        • Villas-Bôas S.G.
        The metabolic basis of Candida albicans morphogenesis and quorum sensing.
        Fungal Genet Biol. 2011; 48: 747-763
        • Lee K.L.
        • Buckley H.R.
        • Campbell C.C.
        An amino acid liquid synthetic medium for the development of mycelial and yeast forms of Candida albicans.
        Sabouraudia. 1975; 13: 148-153
        • Reid G.
        • Kim S.O.
        • Köhler G.A.
        Selecting, testing and understanding probiotic microorganisms.
        FEMS Immunol Med Microbiol. 2006; 46: 149-157
        • Ehrström S1
        • Daroczy K.
        • Rylander E.
        • et al.
        Lactic acid bacteria colonization and clinical outcome after probiotic implementation in conventionally treated bacterial vaginosis and vulvovaginal candidiasis.
        Microbes Infect. 2010; 12: 691-699